Nathalie S Seta

List of Publications by Year
in descending order

148 papers	5,891 citations	71102 41 h-index	95266 68 g-index
164 all docs	164 docs citations	164 times ranked	6032 citing authors

#	Article	IF	Citations
1	Effects of mechanical ventilation on diaphragmatic contractile properties in rats.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1539-1544.	5.6	254
2	Compartmentalized cytokine production within the human lung in unilateral pneumonia.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 710-716.	5.6	233
3	Protein Glycosylation and Diseases: Blood and Urinary Oligosaccharides as Markers for Diagnosis and Therapeutic Monitoring. Clinical Chemistry, 2000, 46, 795-805.	3.2	218
4	A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. Journal of Medical Genetics, 2001, 38, 14-19.	3.2	204
5	Congenital disorders of glycosylation (CDG): Quo vadis?. European Journal of Medical Genetics, 2018, 61, 643-663.	1.3	191
6	Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 336-342.	5.6	151
7	Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies. Brain, 2012, 135, 469-482.	7.6	151
8	Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Human Mutation, 2000, 16, 386-394.	2.5	136
9	Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: A new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose. Journal of Pediatrics, 1999, 135, 379-383.	1.8	127
10	Identification of Mutations in TMEM5 and ISPD as a Cause of Severe Cobblestone Lissencephaly. American Journal of Human Genetics, 2012, 91, 1135-1143.	6.2	126
11	Indoor aldehydes: measurement of contamination levels and identification of their determinants in Paris dwellings. Environmental Research, 2003, 92, 245-253.	7.5	125
12	ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto Î±-dystroglycan. Nature Communications, 2016, 7, 11534.	12.8	113
13	The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 841-843.	3.8	103
14	Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: an updated nomenclature for CDG. First International Workshop on CDGS. Glycoconjugate Journal, 1999, 16, 669-671.	2.7	93
15	International clinical guidelines for the management of phosphomannomutase 2â€congenital disorders of glycosylation: Diagnosis, treatment and follow up. Journal of Inherited Metabolic Disease, 2019, 42, 5-28.	3.6	91
16	Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. Journal of Medical Genetics, 2017, 54, 843-851.	3.2	88
17	Congenital Disorders of Glycosylation Type Ig Is Defined by a Deficiency in Dolichyl-P-mannose:Man7GlcNAc2-PP-dolichyl Mannosyltransferase. Journal of Biological Chemistry, 2002, 277, 25815-25822.	3.4	87
18	Nasal inflammation and personal exposure to fine particles PM2.5 in asthmatic children. Journal of Allergy and Clinical Immunology, 2006, 117, 1382-1388.	2.9	83

#	Article	IF	Citations
19	Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clinical Chemistry, 2000, 46, 795-805.	3.2	82
20	A Deficiency in Dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl Î±3-Glucosyltransferase Defines a New Subtype of Congenital Disorders of Glycosylation. Journal of Biological Chemistry, 2003, 278, 9962-9971.	3.4	78
21	Pesticide exposure of non-occupationally exposed subjects compared to some occupational exposure: A French pilot study. Science of the Total Environment, 2006, 366, 74-91.	8.0	78
22	Secretion of Î±1â€antitrypsin by alveolar epithelial cells. FEBS Letters, 1994, 346, 171-174.	2.8	76
23	New POMT2 mutations causing congenital muscular dystrophy. Neurology, 2007, 69, 1254-1260.	1.1	62
24	Diagnostic value of Western blotting in carbohydrate-deficient glycoprotein syndrome. Clinica Chimica Acta, 1996, 254, 131-140.	1.1	59
25	Risk assessment of acute vascular events in congenital disorder of glycosylation type Ia. Molecular Genetics and Metabolism, 2008, 93, 444-449.	1.1	59
26	Molecular heterogeneity in fetal forms of type II lissencephaly. Human Mutation, 2007, 28, 1020-1027.	2.5	58
27	Assessment and predictor determination of indoor aldehyde levels in Paris newborn babiesâ€™ homes. Indoor Air, 2009, 19, 314-323.	4.3	58
28	Oncostatin M Is a Potent Stimulator of Î±₁-Antitrypsin Secretion in Lung Epithelial Cells: Modulation by Transforming Growth Factor-Î² and Interferon-Î³. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 511-520.	2.9	54
29	Insecticide Urinary Metabolites in Nonoccupationally Exposed Populations. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2005, 8, 485-512.	6.5	54
30	29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype. Orphanet Journal of Rare Diseases, 2014, 9, 207.	2.7	52
31	From splitting GLUT1 deficiency syndromes to overlapping phenotypes. European Journal of Medical Genetics, 2015, 58, 443-454.	1.3	52
32	An in vitro model to evaluate the inflammatory response after gaseous formaldehyde exposure of lung epithelial cells. Toxicology Letters, 2010, 195, 99-105.	0.8	51
33	A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity. Orphanet Journal of Rare Diseases, 2016, 11, 84.	2.7	50
34	Neurological Presentation in Pediatric Patients with Congenital Disorders of Glycosylation Type Ia. Neuropediatrics, 2003, 34, 1-6.	0.6	49
35	Alterations in relative proportions of microheterogenous forms of human Î±1-acid glycoprotein in liver disease. Journal of Hepatology, 1986, 2, 245-252.	3.7	47
36	Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1260-1265.	5.6	47

#	Article	IF	Citations
37	Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-deficient glycoprotein syndrome type Ia disrupting a splicing enhancer resulting in exon 5 skipping. Human Mutation, 1999, 14, 543-544.	2.5	47
38	A rapid mass spectrometric strategy for the characterization ofN- andO-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics, 2007, 7, 1800-1813.	2.2	47
39	Early polysensitization is associated with allergic multimorbidity in PARIS birth cohort infants. Pediatric Allergy and Immunology, 2016, 27, 831-837.	2.6	46
40	Development of liver disease despite mannose treatment in two patients with CDG-Ib. Molecular Genetics and Metabolism, 2008, 93, 40-43.	1.1	44
41	Urinary arsenic concentrations and speciation in residents living in an area with naturally contaminated soils. Science of the Total Environment, 2010, 408, 1190-1194.	8.0	43
42	Neurological presentation of a congenital disorder of glycosylation CDG-Ia: Implications for diagnosis and genetic counseling. American Journal of Medical Genetics Part A, 2001, 101, 46-49.	2.4	40
43	IL6 and acute phase plasma proteins in peritoneal fluid of women with endometriosis. Clinica Chimica Acta, 1992, 210, 187-195.	1.1	39
44	Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase deficiency (congenital) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5(Genetics, 2010, 47, 729-735.	3.2	39
45	SLC10A7 mutations cause a skeletal dysplasia with amelogenesis imperfecta mediated by GAG biosynthesis defects. Nature Communications, 2018, 9, 3087.	12.8	39
46	Inflammatory response modulation of airway epithelial cells exposed to formaldehyde. Toxicology Letters, 2012, 211, 159-163.	0.8	38
47	A new insight into PMM2 mutations in the French population. Human Mutation, 2005, 25, 504-505.	2.5	37
48	Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations. Journal of Hepatology, 1991, 13, 305-309.	3.7	36
49	Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. Neuromuscular Disorders, 2009, 19, 182-188.	0.6	36
50	ALG6â€CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies. Journal of Inherited Metabolic Disease, 2016, 39, 713-723.	3.6	36
51	Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?. Genetics in Medicine, 2019, 21, 1181-1188.	2.4	36
52	Endothelin-1 Secretion by Alveolar Macrophages in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1429-1435.	5.6	35
53	Modifications of Concanavalin A patterns of Î±1-acid glycoprotein and Î±2-HS glycoprotein in alcoholic liver disease. Clinica Chimica Acta, 1988, 176, 49-57.	1.1	34
54	Microheterogeneity of the carbohydrate moiety of human alpha 1-acid glycoprotein in two benign liver diseases: Alcoholic cirrhosis and acute hepatitis. Clinica Chimica Acta, 1989, 186, 59-66.	1.1	34

#	Article	IF	Citations
55	Interleukin-8 and neutrophils in systemic sclerosis with lung involvement.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 1363-1367.	5.6	34
56	Environmental and biological monitoring of exposure to organophosphorus pesticides: Application to occupationally and non-occupationally exposed adult populations. Journal of Exposure Science and Environmental Epidemiology, 2006, 16, 417-426.	3.9	34
57	Protein O-mannosyltransferase activities in lymphoblasts from patients with Î±-dystroglycanopathies. Neuromuscular Disorders, 2008, 18, 45-51.	0.6	33
58	Cardiomyopathy in the congenital disorders of glycosylation (CDG): a case of late presentation and literature review. Journal of Inherited Metabolic Disease, 2009, 32, 313-319.	3.6	32
59	Should PMM2-deficiency (CDG Ia) be searched in every case of unexplained hydrops fetalis?. Molecular Genetics and Metabolism, 2010, 101, 253-257.	1.1	32
60	Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein. Journal of Neuromuscular Diseases, 2015, 2, 27-38.	2.6	32
61	Congenital Disorder of Glycosylation Ia with Deficient Phosphomannomutase Activity but Normal Plasma Glycoprotein Pattern. Clinical Chemistry, 2001, 47, 132-134.	3.2	31
62	A New Intronic Mutation in the DPM1 Gene Is Associated With a Milder Form of CDG Ie in Two French Siblings. Pediatric Research, 2006, 59, 835-839.	2.3	31
63	Allergic sensitisation in early childhood: Patterns and related factors in PARIS birth cohort. International Journal of Hygiene and Environmental Health, 2016, 219, 792-800.	4.3	31
64	Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes. PLoS ONE, 2014, 9, e96916.	2.5	31
65	Congenital disorders of glycosylation IIa cause growth retardation, mental retardation, and facial dysmorphism. Journal of Medical Genetics, 2000, 37, 875-877.	3.2	30
66	In vitro model adapted to the study of skin ageing induced by air pollution. Toxicology Letters, 2016, 259, 60-68.	0.8	30
67	Asthma and allergic rhinitis risk depends on house dust mite specific IgE levels in PARIS birth cohort children. World Allergy Organization Journal, 2019, 12, 100057.	3.5	30
68	A Genome-Wide CRISPR-Cas9 Screen Identifies the Dolichol-Phosphate Mannose Synthase Complex as a Host Dependency Factor for Dengue Virus Infection. Journal of Virology, 2020, 94, .	3.4	30
69	Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation. Electrophoresis, 2018, 39, 3123-3132.	2.4	29
70	Underdiagnosis of mild congenital disorders of glycosylation type Ia. Pediatric Neurology, 2005, 32, 121-123.	2.1	28
71	Congenital disorders of glycosylation type I: a rare but new cause of hyperechoic kidneys in infants and children due to early microcystic changes. Pediatric Radiology, 2006, 36, 108-114.	2.0	28
72	Indoor airborne endotoxin assessment in homes of Paris newborn babies. Indoor Air, 2008, 18, 480-487.	4.3	28

#	Article	IF	Citations
73	A National French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing. European Journal of Human Genetics, 2019, 27, 349-352.	2.8	27
74	Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clinical Pharmacology and Therapeutics, 1988, 44, 458-466.	4.7	26
75	Defect in N-glycosylation of proteins is tissue-dependent in Congenital Disorders of Glycosylation Ia. Glycobiology, 2000, 10, 1277-1281.	2.5	26
76	An in vitro model to evaluate the impact of environmental fine particles (PM0.3-2.5) on skin damage. Toxicology Letters, 2019, 305, 94-102.	0.8	25
77	Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrobial Agents and Chemotherapy, 1991, 35, 1303-1308.	3.2	24
78	Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. Journal of Medical Genetics, 2000, 37, 579-580.	3.2	24
79	Protein losing enteropathy-hepatic fibrosis syndrome in Saguenay-Lac St-Jean, Quebec is a congenital disorder of glycosylation type Ib. Journal of Medical Genetics, 2002, 39, 849-851.	3.2	24
80	Detection of an Alu insertion in the POMT1 gene from three French Walker Warburg syndrome families. Molecular Genetics and Metabolism, 2007, 90, 93-96.	1.1	24
81	Conotruncal heart defects in three patients with congenital disorder of glycosylation type Ia (CDG) Tj ETQq1 1 0.784314 rgBT /Overlock	3.2	24
82	POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation. European Journal of Medical Genetics, 2009, 52, 201-206.	1.3	24
83	Nasal Epithelial and Inflammatory Response to Ozone Exposure: A Review of Laboratory-Based Studies Published Since 1985. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2003, 6, 521-568.	6.5	23
84	Nasal lavage as a tool for the assessment of upper-airway inflammation in adults and children. Translational Research, 2002, 139, 173-180.	2.3	22
85	Sequential airâ€“liquid exposure of human respiratory cells to chemical and biological pollutants. Toxicology Letters, 2011, 207, 53-59.	0.8	22
86	Changes in Î±1-acid glycoprotein serum concentrations and glycoforms in the developing human fetus. Clinica Chimica Acta, 1991, 203, 167-175.	1.1	21
87	Increased recurrence risk in congenital disorders of glycosylation type Ia (CDG-Ia) due to a transmission ratio distortion. Journal of Medical Genetics, 2004, 41, 877-880.	3.2	21
88	A model of human nasal epithelial cells adapted for direct and repeated exposure to airborne pollutants. Toxicology Letters, 2014, 229, 144-149.	0.8	21
89	MALDIâ€TOF MS applied to apoCâ€III glycoforms of patients with congenital disorders affecting Oâ€glycosylation. Comparison with twoâ€dimensional electrophoresis. Proteomics - Clinical Applications, 2015, 9, 787-793.	1.6	20
90	Impact of Mycotoxins Secreted by Aspergillus Molds on the Inflammatory Response of Human Corneal Epithelial Cells. Toxins, 2017, 9, 197.	3.4	20

#	Article	IF	Citations
91	CCDC115-CDG: A new rare and misleading inherited cause of liver disease. Molecular Genetics and Metabolism, 2018, 124, 228-235.	1.1	20
92	Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein. Journal of Neuromuscular Diseases, 2015, 2, 27-38.	2.6	19
93	Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies. Journal of Thrombosis and Haemostasis, 2019, 17, 1798-1807.	3.8	18
94	Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits. Journal of Pharmacology and Experimental Therapeutics, 1989, 251, 311-6.	2.5	18
95	Abnormal Glycosylation of Red Cell Membrane Band 3 in the Congenital Disorder of Glycosylation Ig. Pediatric Research, 2003, 54, 224-229.	2.3	17
96	Dioxins in adipose tissue of non-occupationally exposed persons in France: correlation with individual food exposure. Chemosphere, 2001, 44, 1347-1352.	8.2	16
97	Long term outcome of <scp>MPIâ€CDG</scp> patients on Dâ€mannose therapy. Journal of Inherited Metabolic Disease, 2020, 43, 1360-1369.	3.6	16
98	The T911C (F304S) substitution in the human ALG6 gene is a common polymorphism and not a causal mutation of CDG-Ic. Journal of Human Genetics, 2001, 46, 547-548.	2.3	15
99	Two-dimensional gel electrophoresis of apolipoprotein C-III and other serum glycoproteins for the combined screening of human congenital disorders ofO- andN-glycosylation. Proteomics - Clinical Applications, 2007, 1, 321-324.	1.6	15
100	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. Diabetologia, 2013, 56, 2733-2742.	6.3	14
101	Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrobial Agents and Chemotherapy, 1996, 40, 263-266.	3.2	13
102	Sequential study of serum glycoprotein fucosylation in acute hepatitis. Journal of Hepatology, 1997, 26, 265-271.	3.7	13
103	Absence of Mutation in theSLC2A1Gene in a Cohort of Patients with Alternating Hemiplegia of Childhood (AHC). Neuropediatrics, 2010, 41, 267-269.	0.6	13
104	Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathies. Neuromuscular Disorders, 2011, 21, 782-790.	0.6	13
105	Expanding the Spectrum of PMM2-CDG Phenotype. JIMD Reports, 2011, 5, 123-125.	1.5	13
106	Congenital disorder of glycosylation Ia with deficient phosphomannomutase activity but normal plasma glycoprotein pattern. Clinical Chemistry, 2001, 47, 132-4.	3.2	13
107	Increased Biosynthesis of Glycosphingolipids in Congenital Disorder of Glycosylation Ia (CDG-Ia) Fibroblasts. Pediatric Research, 2002, 52, 645-651.	2.3	12
108	PMM2 intronic branch-site mutations in CDG-Ia. Molecular Genetics and Metabolism, 2006, 87, 337-340.	1.1	12

#	Article	IF	Citations
109	Homozygous Truncating Intragenic Duplication in TUSC3 Responsible for Rare Autosomal Recessive Nonsyndromic Intellectual Disability with No Clinical or Biochemical Metabolic Markers. JIMD Reports, 2014, 20, 45-55.	1.5	12
110	Novel variants and clinical symptoms in four new ALG3â€CDG patients, review of the literature, and identification of AAGRPâ€ALG3 as a novel ALG3 variant with alanine and glycineâ€rich Nâ€terminus. Human Mutation, 2019, 40, 938-951.	2.5	12
111	Serum bikunin isoforms in congenital disorders of glycosylation and linkeropathies. Journal of Inherited Metabolic Disease, 2020, 43, 1349-1359.	3.6	12
112	Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. Antimicrobial Agents and Chemotherapy, 1989, 33, 1506-1510.	3.2	11
113	Two-dimensional electrophoresis highlights haptoglobin beta chain as an additional biomarker of congenital disorders of glycosylation. Clinica Chimica Acta, 2017, 470, 70-74.	1.1	11
114	Comparison of enhanced chemiluminescence and colorimetric techniques for the immuno-detection of Î±1-antitrypsin. Clinica Chimica Acta, 1994, 227, 175-184.	1.1	10
115	Does arsenic in soil contribute to arsenic urinary concentrations in a French population living in a naturally arsenic contaminated area?. Science of the Total Environment, 2010, 408, 6011-6016.	8.0	10
116	Arsenic urinary concentrations in children living in a naturally arsenic contaminated area. Journal of Exposure Science and Environmental Epidemiology, 2013, 23, 145-150.	3.9	10
117	Leukocyte Phosphomannomutase Activity in Diagnosis of Congenital Disorder of Glycosylation Ia. Clinical Chemistry, 2002, 48, 934-936.	3.2	9
118	Partial effectiveness of acetazolamide in a mild form of GLUT1 deficiency: A pediatric observation. Movement Disorders, 2013, 28, 1749-1751.	3.9	9
119	Influence of the environmental relative humidity on the inflammatory response of skin model after exposure to various environmental pollutants. Environmental Research, 2021, 196, 110350.	7.5	9
120	Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits. Antimicrobial Agents and Chemotherapy, 1993, 37, 1790-1798.	3.2	8
121	Serum bikunin is a biomarker of linkeropathies. Clinica Chimica Acta, 2018, 485, 178-180.	1.1	8
122	Wide clinical spectrum in ALG8-CDG: clues from molecular findings suggest an explanation for a milder phenotype in the first-described patient. Pediatric Research, 2019, 85, 384-389.	2.3	8
123	Two dimensional gel electrophoresis of apolipoprotein Câ€II and MALDIâ€TOF MS are complementary techniques for the study of combined defects in Nâ€and mucin type Oâ€glycan biosynthesis. Proteomics - Clinical Applications, 2008, 2, 1670-1674.	1.6	7
124	A Cause of Permanent Ketosis: GLUT-1 Deficiency. JIMD Reports, 2014, 18, 79-83.	1.5	7
125	220th ENMC workshop: Dystroglycan and the dystroglycanopathies Naarden, The Netherlands, 27â€“29 May 2016. Neuromuscular Disorders, 2017, 27, 387-395.	0.6	7
126	Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene. Neuromuscular Disorders, 2019, 29, 497-502.	0.6	7

#	Article	IF	Citations
127	Expanding the phenotype of Xâ€linked SSR4â€“CDG: Connective tissue implications. Human Mutation, 2021, 42, 142-149.	2.5	7
128	A mutation in SLC37A4 causes a dominantly inherited congenital disorder of glycosylation characterized by liver dysfunction. American Journal of Human Genetics, 2021, 108, 1040-1052.	6.2	7
129	Fluorimetric Measurement of Plasma Î±-l-Fucosidase Activity with a Centrifugal Analyzer: Reference Values in a Healthy French Adult Population. Clinical Chemistry, 2000, 46, 560-576.	3.2	6
130	Two Novel Homozygous Mutations in Phosphoglucomutase 3 Leading to Severe Combined Immunodeficiency, Skeletal Dysplasia, and Malformations. Journal of Clinical Immunology, 2021, 41, 958-966.	3.8	6
131	Polyclonal antibody-based enzyme-linked immunosorbent assay of alpha 1-acid glycoprotein. Clinical Chemistry, 1990, 36, 666-668.	3.2	5
132	Effect of the Platelet Activating Factor Antagonist BN52021 in Rabbits: Role in Gentamicin Nephrotoxicity. Toxicology and Applied Pharmacology, 1994, 128, 111-115.	2.8	5
133	Alteration of mannose transport in fibroblasts from type I carbohydrate deficient glycoprotein syndrome patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1453, 369-377.	3.8	5
134	POMGnT1, POMT1, and POMT2 Mutations in Congenital Muscular Dystrophies. Methods in Enzymology, 2010, 479, 343-352.	1.0	5
135	Abnormal Glycosylation Profile and High Alpha-Fetoprotein in a Patient with Twinkle Variants. JIMD Reports, 2016, 29, 109-113.	1.5	5
136	Cell Surface Carbohydrates of Rat Alveolar Type II Cells in Primary Culture. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 145-152.	2.9	4
137	No Mutation in the SLC2A3 Gene in Cohorts of GLUT1 Deficiency Syndromeâ€“Like Patients Negative for SLC2A1 and in Patients with AHC Negative for ATP1A3. JIMD Reports, 2013, 12, 115-120.	1.5	4
138	Human Reconstituted Nasal Epithelium, a promising in vitro model to assess impacts of environmental complex mixtures. Toxicology in Vitro, 2016, 32, 55-62.	2.4	4
139	Nasal inflammation induced by a common cold: comparison between controls and patients with nasal polyposis under topical steroid therapy. Acta Otorhinolaryngologica Italica, 2007, 27, 78-82.	1.5	4
140	Polyclonal antibody-based enzyme-linked immunosorbent assay of alpha 1-acid glycoprotein. Clinical Chemistry, 1990, 36, 666-9.	3.2	2
141	Leukocyte phosphomannomutase activity in diagnosis of congenital disorder of glycosylation Ia. Clinical Chemistry, 2002, 48, 934-6.	3.2	2
142	Le carbohydrate-deficient glycoprotein syndrome typeI : un nouvel Ã©clairage sur le mÃ©tabolisme du mannose.. Medecine/Sciences, 1999, 15, 1202.	0.2	1
143	Factors influencing the reaction of alpha 1-fetoprotein with concanavalin A and Lens culinaris agglutinin in crossed affinoimmunoelectrophoresis. Clinical Chemistry, 1992, 38, 1418-24.	3.2	1
144	An in vitro model to assess the impact on respiratory cells of air pollutants. Toxicology Letters, 2009, 189, S86.	0.8	0

#	Article	IF	Citations
145	Effect of formaldehyde on corneal epithelial cells in an airâ€“liquid culture model. Toxicology Letters, 2011, 205, S120.	0.8	0
146	Experimental elements towards induction of premature skin aging related with tobacco smoke exposure. Toxicology Letters, 2014, 229, S129.	0.8	0
147	Assesment of Effects of Formaldehyde Exposure on Respiratory Health: An Innovative in vitro Model. Epidemiology, 2009, 20, S116.	2.7	0
148	Comparison of glycan microheterogeneities of alpha 1-acid glycoprotein between mothers and their newborns. Progress in Clinical and Biological Research, 1989, 300, 139-42.	0.2	0